突变体
重组DNA
二硫键
突变
化学
生物化学
大肠杆菌
突变蛋白
计算生物学
生物
基因
作者
Lin Zhang,Niju Narayanan,Stephen R. Brand,Charles A. Nicolette,Miren L. Baroja,Jacqueline Arp,Hao Wang,Murray Moo‐Young,C. Perry Chou
标识
DOI:10.1016/j.pep.2010.05.016
摘要
The formation of aberrant disulfide bonds is a structural consideration for the manufacturing of the extracellular domain of human CD83 (hCD83ext), a potential therapeutic protein. In certain instances, hCD83ext protein products, even when stored frozen, tended to dimerize or even multimerize through the formation of aberrant intermolecular disulfide bonds. Herein, we discovered an analytical inconsistency and applied a modified sample preparation protocol for proper structural analysis of hCD83ext products which are heterologously expressed in Escherichia coli and subsequently purified. In addition, a mutant derivative with the Cys100Ser mutation was identified as an improved version which did not form dimers or multimers. The identification of this mutant variant as a more potent therapeutic protein than other hCD83ext species demonstrated that the structural variation associated with disulfide bond formation can be a critical issue for rigorous control of the quality and bioactivity of therapeutic proteins. The application of this mutant variant for protein therapeutics is currently under exploration.
科研通智能强力驱动
Strongly Powered by AbleSci AI